ORCID Profile
0000-0002-3493-4464
Current Organisation
Universidade de São Paulo
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Springer Science and Business Media LLC
Date: 24-08-2023
DOI: 10.1038/S41514-023-00118-0
Abstract: Age is a significant risk factor for the coronavirus disease 2019 (COVID-19) severity due to immunosenescence and certain age-dependent medical conditions (e.g., obesity, cardiovascular disorder, and chronic respiratory disease). However, despite the well-known influence of age on autoantibody biology in health and disease, its impact on the risk of developing severe COVID-19 remains poorly explored. Here, we performed a cross-sectional study of autoantibodies directed against 58 targets associated with autoimmune diseases in 159 in iduals with different COVID-19 severity (71 mild, 61 moderate, and 27 with severe symptoms) and 73 healthy controls. We found that the natural production of autoantibodies increases with age and is exacerbated by SARS-CoV-2 infection, mostly in severe COVID-19 patients. Multiple linear regression analysis showed that severe COVID-19 patients have a significant age-associated increase of autoantibody levels against 16 targets (e.g., amyloid β peptide, β catenin, cardiolipin, claudin, enteric nerve, fibulin, insulin receptor a, and platelet glycoprotein). Principal component analysis with spectrum decomposition and hierarchical clustering analysis based on these autoantibodies indicated an age-dependent stratification of severe COVID-19 patients. Random forest analysis ranked autoantibodies targeting cardiolipin, claudin, and platelet glycoprotein as the three most crucial autoantibodies for the stratification of severe COVID-19 patients ≥50 years of age. Follow-up analysis using binomial logistic regression found that anti-cardiolipin and anti-platelet glycoprotein autoantibodies significantly increased the likelihood of developing a severe COVID-19 phenotype with aging. These findings provide key insights to explain why aging increases the chance of developing more severe COVID-19 phenotypes.
Publisher: Wiley
Date: 13-01-2023
DOI: 10.1002/JMV.28450
Abstract: Several perturbations in the number of peripheral blood leukocytes, such as neutrophilia and lymphopenia associated with Coronavirus disease 2019 (COVID‐19) severity, point to systemic molecular cell cycle alterations during severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection. However, the landscape of cell cycle alterations in COVID‐19 remains primarily unexplored. Here, we performed an integrative systems immunology analysis of publicly available proteome and transcriptome data to characterize global changes in the cell cycle signature of COVID‐19 patients. We found significantly enriched cell cycle‐associated gene co‐expression modules and an interconnected network of cell cycle‐associated differentially expressed proteins (DEPs) and genes (DEGs) by integrating the molecular data of 1469 in iduals (981 SARS‐CoV‐2 infected patients and 488 controls [either healthy controls or in iduals with other respiratory illnesses]). Among these DEPs and DEGs are several cyclins, cell ision cycles, cyclin‐dependent kinases, and mini‐chromosome maintenance proteins. COVID‐19 patients partially shared the expression pattern of some cell cycle‐associated genes with other respiratory illnesses but exhibited some specific differential features. Notably, the cell cycle signature predominated in the patients' blood leukocytes (B, T, and natural killer cells) and was associated with COVID‐19 severity and disease trajectories. These results provide a unique global understanding of distinct alterations in cell cycle‐associated molecules in COVID‐19 patients, suggesting new putative pathways for therapeutic intervention.
Publisher: Elsevier BV
Date: 05-2023
Location: Brazil
No related grants have been discovered for Igor Salerno Filgueiras.